KYMR

Kymera Therapeutics, Inc. [KYMR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KYMR Stock Summary

Top 10 Correlated ETFs

KYMR


Top 10 Correlated Stocks

KYMR


In the News

07:00 28 Mar 2024 KYMR

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

07:00 28 Mar 2024 KYMR

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.

07:00 28 Mar 2024 KYMR

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.

07:00 28 Mar 2024 KYMR

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D., Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2024.

12:48 28 Mar 2024 KYMR

Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474

Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.

05:49 28 Mar 2024 KYMR

Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian

Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.

02:27 28 Mar 2024 KYMR

Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases

Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentiment is mixed, with high short interest and cautious institutional and insider activities reflecting investor skepticism.

01:10 28 Mar 2024 KYMR

Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B.

07:00 28 Mar 2024 KYMR

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming investor events:

07:00 28 Mar 2024 KYMR

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report third quarter 2023 financial results on November 2, 2023, and will host a conference call at 8:00 a.m. ET that day.

KYMR Financial details

Company Rating
Neutral
Market Cap
2.49B
Income
-142.62M
Revenue
78.59M
Book val./share
6.75
Cash/share
6.41
Dividend
-
Dividend %
-
Employees
187
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-10.25
Forward P/E
-11.44
PEG
7.81
P/S
33.73
P/B
4.21
P/C
6.27
P/FCF
-9.1
Quick Ratio
5.72
Current Ratio
5.95
Debt / Equity
0.21
LT Debt / Equity
0.2
-
-
EPS (TTM)
-2.45
EPS next Y
-3.51
EPS next Q
-0.71
EPS this Y
-99.91%
EPS next Y
43.11%
EPS next 5Y
55.42%
EPS last 5Y
-71.67%
Revenue last 5Y
93.01%
Revenue Q/Q
912.8%
EPS Q/Q
-72.22%
-
-
-
-
SMA20
-2.72%
SMA50
44.15%
SMA100
244.16%
Inst Own
67.59%
Inst Trans
0.68%
ROA
-29%
ROE
-36%
ROC
-0.38%
Gross Margin
100%
Oper. Margin
-395%
Profit Margin
-346%
Payout
-
Shs Outstand
61.11M
Shs Float
54.16M
-
-
-
-
Target Price
46.33
52W Range
9.6-45.31
52W High
-10.73%
52W Low
+346.33%
RSI
51.89
Rel Volume
0.73
Avg Volume
839.65K
Volume
612.53K
Perf Week
2.16%
Perf Month
14.67%
Perf Quarter
161.35%
Perf Half Y
163.41%
-
-
-
-
Beta
2.301
-
-
Volatility
0.53%, 1.89%
Prev Close
1.72%
Price
40.17
Change
0.43%

KYMR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.11.961.520.870
Net income per share
-1.37-2.53-2.04-2.820
Operating cash flow per share
0.595.08-2.69-2.840
Free cash flow per share
0.584.56-2.72-2.890
Cash per share
3.0517.079.227.550.01
Book value per share
-2.4616.369.589.090.01
Tangible book value per share
-2.4616.369.589.090.01
Share holders equity per share
-2.4616.369.589.090.01
Interest debt per share
0.71.040.380.320
Market cap
1B1.08B3.05B1.35B1485.99B
Enterprise value
949.47M1.06B3.02B1.3B1485.96B
P/E ratio
-24.32-24.48-31.09-8.87-10.11K
Price to sales ratio
342.2931.6141.8328.7518.91K
POCF ratio
56.0912.21-23.63-8.79-14.45K
PFCF ratio
57.8113.61-23.34-8.63-10.82K
P/B Ratio
-13.53.796.632.753.76K
PTB ratio
-13.53.796.632.753.76K
EV to sales
323.6131.2241.4227.6618.91K
Enterprise value over EBITDA
-23.52-23.37-30.16-8.38-10.38K
EV to operating cash flow
53.0312.06-23.4-8.46-14.45K
EV to free cash flow
54.6513.45-23.11-8.31-10.82K
Earnings yield
-0.04-0.04-0.03-0.110
Free cash flow yield
0.020.07-0.04-0.120
Debt to equity
-0.280.060.040.040.21
Debt to assets
0.180.040.030.030.15
Net debt to EBITDA
1.360.290.30.330.18
Current ratio
2.692.735.628.844.73
Interest coverage
-917.5-402.64-574.46-916.23-844.54
Income quality
-0.43-1.931.290.990.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.720.540.50.940.7
Research and developement to revenue
12.661.821.883.512.41
Intangibles to total assets
00000
Capex to operating cash flow
-0.03-0.10.010.020.34
Capex to revenue
-0.18-0.27-0.02-0.06-0.44
Capex to depreciation
-0.64-5.16-0.67-0.95-9.67
Stock based compensation to revenue
0.410.150.340.760.55
Graham number
8.7130.5420.9823.990.02
ROIC
1.32-0.14-0.2-0.3-0.33
Return on tangible assets
-0.35-0.09-0.16-0.25-0.26
Graham Net
-3.280.716.085.380
Working capital
58.28M191.72M466.57M496.23M319.63M
Tangible asset value
-74.41M283.89M459.64M490.15M394.97M
Net current asset value
-98.26M99.05M421.34M446.51M224.53M
Invested capital
-0.280.060.040.040.21
Average receivables
74K716.5K784K1.34M10.65M
Average payables
2.67M3.82M4.19M4.17M5.71M
Average inventory
0-81.69M-86.19M-10.62M-6.13M
Days sales outstanding
015.370.6819.7887.14
Days payables outstanding
1.45K25.67609.86531.5724.37
Days of inventory on hand
0-960.25-1.37K-1.5K0
Receivables turnover
023.75539.518.464.19
Payables turnover
0.2514.220.60.690.5
Inventory turnover
0-0.38-0.27-0.240
ROE
0.55-0.15-0.21-0.31-0.37
Capex per share
-0.02-0.52-0.03-0.050

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.280.160.280.080.82
Net income per share
-0.59-0.63-0.67-0.9-0.25
Operating cash flow per share
-0.68-0.76-0.6-0.540.14
Free cash flow per share
-0.69-0.82-0.79-0.68-0.06
Cash per share
7.036.826.36.126.41
Book value per share
8.477.947.476.776.75
Tangible book value per share
8.477.947.476.776.75
Share holders equity per share
8.477.947.476.776.75
Interest debt per share
0.32.261.291.381.45
Market cap
1.44B1.72B1.34B812.06M1.49B
Enterprise value
1.39B1.74B1.36B811.86M1.46B
P/E ratio
-10.61-11.78-8.64-3.84-25.93
Price to sales ratio
89.53182.1381.2171.7631.12
POCF ratio
-36.55-39.21-38.03-25.66185.2
PFCF ratio
-36.21-35.94-29.14-20.44-416.19
P/B Ratio
2.953.733.082.053.77
PTB ratio
2.953.733.082.053.77
EV to sales
86.37183.8582.58171.7130.59
Enterprise value over EBITDA
-40.05-42.58-36.03-14.12-109.1
EV to operating cash flow
-35.26-39.58-38.68-25.65182.06
EV to free cash flow
-34.93-36.27-29.63-20.44-409.13
Earnings yield
-0.02-0.02-0.03-0.07-0.01
Free cash flow yield
-0.03-0.03-0.03-0.050
Debt to equity
0.040.280.170.20.21
Debt to assets
0.030.210.130.150.15
Net debt to EBITDA
1.47-0.4-0.601.88
Current ratio
8.844.187.065.954.73
Interest coverage
-666.05-824.11-903.811.4K-371.38
Income quality
1.131.070.910.6-0.56
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.721.330.862.990.3
Research and developement to revenue
2.674.462.7710.181.11
Intangibles to total assets
00000
Capex to operating cash flow
0.010.090.310.26-1.44
Capex to revenue
-0.02-0.42-0.65-1.71-0.24
Capex to depreciation
-0.46-4.56-11.96-9.03-13.05
Stock based compensation to revenue
0.550.990.682.470.23
Graham number
10.5910.610.5711.746.11
ROIC
-0.07-0.06-0.08-0.1-0.05
Return on tangible assets
-0.06-0.06-0.07-0.1-0.02
Graham Net
5.014.133.843.493.56
Working capital
496.23M392.35M330.8M312.53M319.63M
Tangible asset value
490.15M462.01M435.43M395.54M394.97M
Net current asset value
446.51M363.99M238.89M218.85M224.53M
Invested capital
0.040.280.170.20.21
Average receivables
2.71M2.93M3.72M3.95M11.27M
Average payables
5.33M5.41M5.11M4.36M6.03M
Average inventory
-6.13M-13.46M-7.34M0.50
Days sales outstanding
14.1531.5722.4771.9235.26
Days payables outstanding
476.96648.3374.5497.8736.13
Days of inventory on hand
-1.35K-1.47K000
Receivables turnover
6.362.854.011.252.55
Payables turnover
0.190.140.240.180.12
Inventory turnover
-0.07-0.06900K00
ROE
-0.07-0.08-0.09-0.13-0.04
Capex per share
-0.01-0.07-0.18-0.14-0.2

KYMR Frequently Asked Questions

What is Kymera Therapeutics, Inc. stock symbol ?

Kymera Therapeutics, Inc. is a US stock , located in Watertown of Ma and trading under the symbol KYMR

Is Kymera Therapeutics, Inc. buy or a sell ?

11 stock analysts have 11 predictions with a medium analyst target price of $46.93. The lowest prediction is $31 and the highest is $80

What is KYMR stock prediction ?

What is Kymera Therapeutics, Inc. stock quote today ?

Kymera Therapeutics, Inc. stock price is $40.17 today.

Is Kymera Therapeutics, Inc. stock public?

Yes, Kymera Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks